AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celyad Oncology SA Announces Capital Increase and Update on Total Number of Voting Rights and Shares
ByAinvest
Thursday, Aug 7, 2025 12:36 pm ET1min read
Celyad Oncology SA has increased its share capital to EUR 9,216,154.53 and is now represented by 44,761,905 shares. The company has issued 3,333,333 new shares to an affiliate of Fortress Investment Group. The total number of voting rights is 53,630,280, and the total number of diluted shares is 48,618,039.
Title: Celyad Oncology SA Increases Share Capital and Total Number of SharesMont-Saint-Guibert, Belgium — Celyad Oncology SA (Euronext: CYAD) has announced a significant increase in its share capital and total number of shares, following the issuance of 3,333,333 new shares to an affiliate of Fortress Investment Group. The company's share capital has been augmented to EUR 9,216,154.53, represented by 44,761,905 shares [1].
The new shares have increased the total number of shares with single voting rights to 35,893,530 and the total number of shares with double voting rights to 8,868,375. Consequently, the total number of voting rights has risen to 53,630,280. Additionally, the total number of diluted shares, including attributed warrants, stands at 48,618,039 [1].
This capital increase aligns with Celyad Oncology's strategic business model, which includes the development of its proprietary CAR-T technology platforms and intellectual property. The company's forward-looking statements highlight potential benefits from its updated strategic business model, including associated transactions and partnerships, and statements regarding the potential value of its IP assets [1].
The announcement follows the issuance of 3,333,333 new shares, which has increased the total number of shares and voting rights. This move signifies Celyad Oncology's commitment to growth and its ability to attract investment from prominent entities like Fortress Investment Group. The company's strategic focus on its CAR-T technology platforms and intellectual property underscores its commitment to innovation and the development of cutting-edge biotechnology solutions [1].
For further information, investors are encouraged to contact Matthew Kane, Chief Executive Officer (CEO), at investors@celyad.com.
References:
[1] https://www.stocktitan.net/news/CYAD/celyad-oncology-sa-information-on-the-total-number-of-voting-rights-5aovj2bu5ws8.html
[2] https://www.nasdaq.com/articles/cipher-mining-cifr-q2-eps-surges
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet